Sai Sheng Pharmaceutical's subsidiary, Saier Biological, has received acceptance for its Dagliflozin Tablets drug registration and marketing license application from China's National Medical Products Administration. This medication works by reducing blood sugar through inhibiting renal glucose reabsorption, offering a low risk of hypoglycemia, no weight gain, and mild gastrointestinal side effects. Separately, Jianyou Co., Ltd.'s subsidiary, Emerge Bioscience Pte. Ltd., has obtained approval from the U.S. FDA for its Insulin Aspart Injection BLA, which is used to improve glycemic control in adult and pediatric diabetes patients. AI
IMPACT N/A
RANK_REASON The cluster reports on drug approvals, which are product-related but not frontier AI releases.
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →
